Alzamend Neuro (ALZN) said Tuesday it is now in compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement for continued listing.
Earlier this year, the company agreed to sell $25 million of its series A convertible preferred stock to an investor over a period of time. Alzamend said the investor has so far bought $8 million of the shares, with an additional $2 million to be funded within the next 30 days.
The investor is obligated to buy $1 million of the shares every month until January 2026, the company said.
The company's shares were down 4.2% in recent trading.
Price: 1.61, Change: -0.07, Percent Change: -4.17
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。